Fulgent Genetics, Inc.

FLGT Healthcare Diagnostics & Research

Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.

19.81 1.53 −7.17%
Market cap
$587.2M
P/E
0.0×
Fwd P/E
−5.8×
Dividend yield
—
F-score
4/9
Altman Z
5.63
Beneish M
−2.35
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
2.20 2.51 1.53 1.77
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
62.57 (10.35) 69.19 (24.19)
P/B ratio
0.62 0.73 0.47 0.58
EV/Sales
1.08 1.53 0.74 1.05
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(17.14) (3.97) (2.08) (3.26)
Current Ratio
7.01 6.48 5.31 6.34
Net Debt/EBITDA
778.06 8.20 9.36 8.82
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(6.15%) (7.46%) (15.03%) (13.74%)
Free Cash Flow Yield
(2.86%) (15.36%) (23.05%) (18.06%)
Free Cash Flow per Share
0.16 (2.70) 0.06 (0.99)
Book value per Share
36.45 35.96 33.81 35.56
Free Cash Flow
5.06 (83.12) 1.90 (27.62)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates